JEMIQTA Trademark

Trademark Overview


On Monday, July 14, 2025, a trademark application was filed for JEMIQTA with the United States Patent and Trademark Office. The USPTO has given the JEMIQTA trademark a serial number of 99281818. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, December 3, 2025. This trademark is owned by H. Lundbeck A/S. The JEMIQTA trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Medical apparatus, namely, infusion and injection devices for administering drugs; Medical syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for administering medicines, incorporating downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; Medical devices and instruments for use in the diagnosis, medicine administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems comprising of medical instruments for diagnostics a...

Sanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases of, generated from and affecting the central nervous system; pharmaceutical preparations and substances for the treatment of central nervous system disorders; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior syndrome, porphyria, Huntington...
jemiqta

General Information


Serial Number99281818
Word MarkJEMIQTA
Filing DateMonday, July 14, 2025
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateWednesday, December 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 23, 2025

Trademark Statements


Goods and ServicesMedical apparatus, namely, infusion and injection devices for administering drugs; Medical syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for administering medicines, incorporating downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; Medical devices and instruments for use in the diagnosis, medicine administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems comprising of medical instruments for diagnostics and examination of patients and downloadable software for processing patient intake and communications and information management, all for use in the examination and assessment of patients and clients; integrated medical systems comprised of medical instruments for treating central nervous system diseases and disorders and psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases, all for the purposes of management, measurement, monitoring, evaluation, control, collection, storage, transmission and examination of patient and client data and information; medical instruments, namely, devices for delivery and administering of medicines in the nature of infusion and injection devices and infusion pumps for providing medication administering information, guidance, and management
Goods and ServicesSanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases of, generated from and affecting the central nervous system; pharmaceutical preparations and substances for the treatment of central nervous system disorders; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior syndrome, porphyria, Huntington's disease, insomnia, Parkinson's disease, sclerosis, multiple sclerosis, schizophrenia, bipolar disorder, cancer, pain, migraine, headache, Horton's headache, traumatic brain injury, post-traumatic brain injury, dizziness, seizures, stroke, cognitive impairment, cognitive disorders and diseases, mood disorders, falls, movement disorders and diseases, tremor, agitation, mania, aggression, autism, melancholia, Obsessive Compulsive Disorder (OCD), Tourette's syndrome, restlessness, akathisia, fatigue, somnolence, nausea, Cushing's disease, Adrenogenital syndrome (AGS), narcolepsy, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Progressive Supranuclear Palsy (PSP), Thyroid Associated Orbitopathy (TAO), Graves Orbitopathy, Hashimoto's Thyroiditis, alcoholism and addiction; diagnostic agents and preparations for medical purposes; chemical substances for diagnostic and medical purposes, namely, chemical reagents for medical use, diagnostic chemical reagents for medical purposes; medical diagnostic reagents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 14, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateMonday, July 14, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameH. Lundbeck A/S
Party Type10 - Original Applicant
Legal Entity Type65 - NOT AVAILABLE
AddressValby 2500
DK

Trademark Events


Event DateEvent Description
Monday, July 14, 2025NEW APPLICATION ENTERED
Monday, July 14, 2025APPLICATION FILING RECEIPT MAILED
Monday, July 14, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 19, 2025ASSIGNED TO EXAMINER
Tuesday, September 23, 2025NON-FINAL ACTION WRITTEN
Tuesday, September 23, 2025NON-FINAL ACTION E-MAILED
Tuesday, September 23, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 24, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 24, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 24, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 25, 2025APPROVED FOR PUB - PRINCIPAL REGISTER